Fluoxetine

Generic Name: Fluoxetine

Brand Names: Prozac, Sarafem, Symbyax

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈F_₃NO

CAS Number: 54910-89-3

Unique Ingredient Identifier: 01K63SUP8D

Background: Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.

Indication: Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present. Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar I Disorder, and treatment resistant depression. Fluoxetine is additionally indicated for the treatment of female patients with premenstrual dysphoric disorder (PMDD).

Associated Conditions: Alcohol Dependency, Anorexia Nervosa (AN), Bulimia Nervosa, Cataplexy, Depression, Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Myoclonus, Obesity, Obsessive Compulsive Disorder (OCD), Panic Disorder With Agoraphobia, Panic disorder without agoraphobia, Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD)

Associated Therapies: Maintenance therapy

Clinical Trials

Algorithm Guided Treatment Strategies for Major Depressive Disorder

Phase 4

Conditions: Major Depressive Disorder

Interventions: Drug: Escitalopram
Drug: Fluoxetine
Drug: Mirtazapine
Drug: Citalopram
Other: modified electroconvulsive therapy
Other: repetitive transcranial magnetic stimulation
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Venlafaxine
Drug: Duloxetine
Drug: Bupropion
Drug: Trazodone

First Posted Date: 2013-01-10

Last Posted Date: 2013-01-10

Lead Sponsor: Shanghai Mental Health Center

Target Recruit Count: 1080

Registration Number: NCT01764867

Locations: 🇨🇳
Shanghai Mental Health Center, Shanghai, China

Comparison of Behavioral Activation and Antidepressant Medication in the Treatment of Adolescents With Depression

Not Applicable

Terminated

Conditions: Major Depressive Disorder

Interventions: Behavioral: Behavioral Activation
Drug: Fluoxetine

First Posted Date: 2012-12-04

Last Posted Date: 2017-12-20

Lead Sponsor: Emory University

Target Recruit Count: 3

Registration Number: NCT01740726

Locations: 🇺🇸
Emory Executive Park, Atlanta, Georgia, United States

Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage

Phase 3

Terminated

Conditions: Intracerebral Hemorrhage
Motor Impairment

Interventions: Drug: Placebo
Drug: Fluoxetine

First Posted Date: 2012-11-29

Last Posted Date: 2014-08-22

Lead Sponsor: Universidad Autónoma de Aguascalientes

Target Recruit Count: 32

Registration Number: NCT01737541

Locations: 🇲🇽
Hospital General de Zona #1, Aguascalientes, Mexico
🇲🇽
Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico
🇲🇽
Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico

and more 1 locations

Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation

Phase 2

Completed

Conditions: Severe Mood Dysregulation

Interventions: Drug: lisdexamfetamine
Drug: Placebo
Drug: fluoxetine

First Posted Date: 2012-10-25

Last Posted Date: 2018-02-26

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 34

Registration Number: NCT01714310

Locations: 🇺🇸
UCLA Semel Institute, Los Angeles, California, United States

A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression

Phase 3

Terminated

Conditions: Treatment Resistant Depression

Interventions: Drug: Olanzapine
Drug: Fluoxetine
Drug: Placebo

First Posted Date: 2012-09-19

Last Posted Date: 2019-10-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 176

Registration Number: NCT01687478

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Xinxiang, China